Pharma News

The FDA granted fast track designation to ALLO-316, an investigational chimeric antigen receptor T-cell therapy, for the treatment of adults with advanced or metastatic clear cell renal cell carcinoma...

Pfizer will gain access to Arena’s portfolio of various treatment candidates for gastroenterology, dermatology and cardiology.

On March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleter...

Investigators at Cedars-Sinai have identified a potential new therapy for COVID-19: a biologic substance created by reengineered human skin cells.

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in ...

Physicists, chemists and immunologists at McMaster University have teamed up to modify red blood cells to transport viral agents which can safely trigger the immune system to protect the body again...

Clinical-stage biotechnology company, Abivax, has reported promising results from its phase 2a maintenance trial into rheumatoid arthritis (RA) after one year of continued daily treatment with 50m...

AbbVie and Gedeon Richter have entered an agreement for researching, developing and marketing new dopamine receptor modulators to potentially treat neuropsychiatric diseases.  ...

Pfizer has launched a phase 2/3 trial evaluating its COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir) in pediatric patients with symptomatic COVID-19 who haven’t been hospitalized. ...

Hybrid versions of the coronavirus that combine genes from the Delta and Omicron variants - dubbed "Deltacron" - have been identified in at least 17 patients in the United States and Europe, researche...

The EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.

The US Food and Drug Administration (FDA) has granted approval to Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) plus platinum-doublet chemotherapy for adult resectable non-small cell lung cance...